These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25636935)

  • 1. HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients.
    Gianotti N; Canducci F; Galli L; Cossarini F; Salpietro S; Poli A; Nozza S; Spagnuolo V; Clementi M; Sampaolo M; Ceresola ER; Racca S; Lazzarin A; Castagna A
    Clin Microbiol Infect; 2015 Jan; 21(1):103.e7-103.e10. PubMed ID: 25636935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL.
    Gianotti N; Galli L; Racca S; Salpietro S; Cossarini F; Spagnuolo V; Barda B; Canducci F; Clementi M; Lazzarin A; Castagna A
    J Antimicrob Chemother; 2012 Jan; 67(1):213-7. PubMed ID: 21987242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up.
    Gianotti N; Galli L; Salpietro S; Cernuschi M; Bossolasco S; Maillard M; Spagnuolo V; Canducci F; Clementi M; Lazzarin A; Castagna A
    Clin Microbiol Infect; 2013 Dec; 19(12):E542-4. PubMed ID: 23890370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy.
    Zheng L; Bosch RJ; Chan ES; Read S; Kearney M; Margolis DM; Mellors JW; Eron JJ; Gandhi RT;
    Antivir Ther; 2013; 18(1):39-43. PubMed ID: 22914318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of pre-therapy viral load on virological response to modern first-line HAART.
    Santoro MM; Armenia D; Alteri C; Flandre P; Calcagno A; Santoro M; Gori C; Fabeni L; Bellagamba R; Borghi V; Forbici F; Latini A; Palamara G; Libertone R; Tozzi V; Boumis E; Tommasi C; Pinnetti C; Ammassari A; Nicastri E; Buonomini A; Svicher V; Andreoni M; Narciso P; Mussini C; Antinori A; Ceccherini-Silberstein F; Di Perri G; Perno CF
    Antivir Ther; 2013; 18(7):867-76. PubMed ID: 23343501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy.
    Sungkanuparph S; Groger RK; Overton ET; Fraser VJ; Powderly WG
    HIV Med; 2006 Oct; 7(7):437-41. PubMed ID: 16925729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173.
    Gandhi RT; Bosch RJ; Aga E; Bedison MA; Bastow B; Schmitz JL; Siliciano JD; Siliciano RF; Eron JJ; Mellors JW;
    Antivir Ther; 2013; 18(4):607-13. PubMed ID: 23411421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation.
    Laprise C; de Pokomandy A; Baril JG; Dufresne S; Trottier H
    Clin Infect Dis; 2013 Nov; 57(10):1489-96. PubMed ID: 23946221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation.
    Bonora S; Nicastri E; Calcagno A; Gonzalez de Requena D; D'Ettorre G; Sarmati L; Palmisano L; Vullo V; Di Perri G; Andreoni M
    J Med Virol; 2009 Mar; 81(3):400-5. PubMed ID: 19152404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen.
    Armenia D; Di Carlo D; Cozzi-Lepri A; Calcagno A; Borghi V; Gori C; Bertoli A; Gennari W; Bellagamba R; Castagna A; Latini A; Pinnetti C; Cicalini S; Saracino A; Lapadula G; Rusconi S; Castelli F; Di Giambenedetto S; Andreoni M; Di Perri G; Antinori A; Mussini C; Ceccherini-Silberstein F; Monforte AD; Perno CF; Santoro MM;
    Antivir Ther; 2019; 24(5):321-331. PubMed ID: 30977466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 DNA and RNA kinetics in primary HIV infection.
    Lillo F; Grasso M; Lodini S; Capiluppi B; Lazzarin A; Tambussi G
    J Biol Regul Homeost Agents; 2002; 16(1):49-52. PubMed ID: 12003174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 Very Low Level Viremia Is Associated with Virological Failure in Highly Active Antiretroviral Treatment-Treated Patients.
    Calcagno A; Motta I; Ghisetti V; Lo Re S; Allice T; Marinaro L; Milia MG; Tettoni MC; Trentini L; Orofino G; Salassa B; Di Perri G; Bonora S
    AIDS Res Hum Retroviruses; 2015 Oct; 31(10):999-1008. PubMed ID: 26165150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.
    Masquelier B; Pereira E; Peytavin G; Descamps D; Reynes J; Verdon R; Fleury H; Garraffo R; Chêne G; Raffi F; Brun-Vézinet F;
    J Clin Virol; 2005 May; 33(1):75-8. PubMed ID: 15797369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success.
    Alteri C; Scutari R; Stingone C; Maffongelli G; Brugneti M; Falasca F; Martini S; Bertoli A; Turriziani O; Sarmati L; Coppola N; Andreoni M; Santoro MM; Perno CF; Ceccherini-Silberstein F; Svicher V
    J Clin Virol; 2019 Aug; 117():61-67. PubMed ID: 31229934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
    Havlir DV; Koelsch KK; Strain MC; Margot N; Lu B; Ignacio CC; Miller MD; Wong JK;
    J Infect Dis; 2005 Apr; 191(7):1164-8. PubMed ID: 15747253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA.
    Gianella S; von Wyl V; Fischer M; Niederoest B; Battegay M; Bernasconi E; Cavassini M; Rauch A; Hirschel B; Vernazza P; Weber R; Joos B; Günthard HF;
    Antivir Ther; 2011; 16(4):535-45. PubMed ID: 21685541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Very high baseline HIV viremia impairs efficacy of non-nucleoside reverse transcriptase inhibitor-based ART: a long-term observation in treatment-naïve patients.
    Chen S; Han Y; Song XJ; Li YL; Zhu T; Lu HZ; Tang XP; Zhang T; Zhao M; He Y; He SH; Wang M; Li YZ; Huang SB; Li Y; Liu J; Cao W; Li TS
    Infect Dis Poverty; 2020 Jun; 9(1):75. PubMed ID: 32571409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-level viremia is associated with non-B subtypes in patients infected with HIV with virological success following HAART introduction.
    Saison J; Tardy JC; Scholtes C; Icard V; Trabaud MA; Perpoint T; Chidiac C; Ecochard R; André P; Ferry T;
    J Med Virol; 2013 Jun; 85(6):953-8. PubMed ID: 23588720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians.
    Souza IE; Zhang W; Diaz RS; Chaloner K; Klinzman D; Stapleton JT
    HIV Med; 2006 Jan; 7(1):25-31. PubMed ID: 16313289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.